Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
TNF-α downregulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding
Lee A. Denson, … , Carol R. Williams, Saul J. Karpen
Lee A. Denson, … , Carol R. Williams, Saul J. Karpen
Published June 1, 2001
Citation Information: J Clin Invest. 2001;107(11):1451-1458. https://doi.org/10.1172/JCI10994.
View: Text | PDF
Article

TNF-α downregulates murine hepatic growth hormone receptor expression by inhibiting Sp1 and Sp3 binding

  • Text
  • PDF
Abstract

Children with chronic inflammatory diseases experience growth failure and wasting. This may be due to growth hormone resistance caused by cytokine-induced suppression of growth hormone receptor (GHR) gene expression. However, the factors governing inflammatory regulation of GHR are not known. We have reported that Sp1 and Sp3 regulate hepatic GHR expression. We hypothesized that TNF-α suppresses GHR expression by inhibiting Sp1/Sp3 transactivators. LPS administration significantly reduced murine hepatic GHR expression, as well as Sp1 and Sp3 binding to GHR promoter cis elements. TNF-α was integral to this response, as LPS did not affect hepatic Sp1/Sp3 binding or GHR expression in TNF receptor 1–deficient mice. TNF-α treatment of BNL CL.2 mouse liver cells reduced Sp1 and Sp3 binding to a GHR promoter cis element and downregulated activity of a GHR promoter-driven luciferase reporter. Combined mutations within adjacent Sp elements eliminated GHR promoter suppression by TNF-α without affecting overall nuclear levels of Sp1 or Sp3 proteins. These studies demonstrate that murine GHR transcription is downregulated by LPS, primarily via TNF-α–dependent signaling. Evidence suggests that inhibition of Sp transactivator binding is involved. Further investigation of these mechanisms may identify novel strategies for preventing inflammatory suppression of growth.

Authors

Lee A. Denson, Ram K. Menon, Angel Shaufl, Himmat S. Bajwa, Carol R. Williams, Saul J. Karpen

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
TNF-α downregulates GHR L2 promoter activity via the L2A and L2B Sp resp...
TNF-α downregulates GHR L2 promoter activity via the L2A and L2B Sp response elements. (a) WT and mutated GHR L2 promoter luciferase reporter constructs were transiently transfected in mouse liver BNL CL.2 cells and treated with TNF-α (10 ng/ml for 12 hours). Luciferase-specific activity in the cell homogenates was equalized for transfection efficiency monitored by cotransfection of a plasmid expressing β-gal (RLU/βGAL). Data are expressed as the mean ± SEM of three independent transfections performed in triplicate. AP < 0.05 versus control for each plasmid with TNF treatment. BP < 0.05 versus L2 control plasmid for basal activity. (b) EMSA was performed using mouse liver nuclear proteins and L2A, L2B, L2M1, and L2M3 oligonucleotides.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts